Clinical Trial Update: An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303

View source ↗

Summary

This update announces an Extended Access Program for participants who completed the Rufinamide study E2080-G000-303, providing continued access to Rufinamide fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lennox-gastaut Syndrome

Drugs mentioned

• Banzel (rufinamide)

Snippet

Sponsor: Eisai Inc. | Conditions: Lennox Gastaut Syndrome | Status: AVAILABLE